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Yeasts and filamentous fungi are beginning to emerge as significant microbial pathogens in patients with cystic fibrosis (CF), particularly in
relation to allergic-type responses, as seen in patients with allergic bronchopulmonary aspergillosis (ABPA), Aspergillus bronchitis and in invasive
fungal disease in lung transplant patients. Four fungal media were compared in this study, including Sabouraud Dextrose Agar (SDA) and
Medium B, with and without the addition of selective antibiotics, where antibiotic-supplemented media were designated with +. These media were
compared for their ability to suppress contaminating, mainly Gram−ve pathogens, in CF sputa (Pseudomonas aeruginosa, Burkholderia cepacia
complex [BCC] organisms) and to enhance the growth of fungi present in CF sputum. Medium B consisted of glucose (16.7 g/l), agar (20 g/l),
yeast extract (30 g/l) and peptone (6.8 g/l) at pH 6.3 and both SDA+ and Medium B+ were supplemented with cotrimethoxazole, 128 mg/l;
chloramphenicol, 50 mg/l; ceftazidime, 32 mg/l; colistin, 24 mg/l). Employment of SDA+ or Medium B+ allowed an increase in specificity in the
detection of yeasts and moulds, by 42.8% and 39.3%, respectively, over SDA when used solely. SDA+ had a greater ability than Medium B+ to
suppress bacterial growth from predominantly Gram−ve co-colonisers. This is a significant benefit when attempting to detect and isolate fungi
from the sputum of CF patients, as it largely suppressed any bacterial growth, with the exception of the BCC organisms, thus allowing for an
increased opportunity to detect target fungal organisms in sputum and represented a significant improvement over the commercial medium (SDA),
which is currently used. Overall, both novel selective media were superior in their ability to suppress bacteria in comparison with the
commercially available SDA medium, which is routinely employed in most clinical microbiology diagnostic laboratories presently. Alternatively,
Medium B+ had a great ability to grow fungi than SDA+ and when employed together, the specificity of combined use was 82%, with a sensitivity
for yeasts, filamentous fungi, and combined overall fungi of 96.0%, 92.3% and 96.0%, respectively. Overall, when employing one fungal selective
medium for the routine detection of yeasts and filamentous fungi in the sputum of CF patients, we would recommend employment of Medium B+.
However, we would recommend the combined employment of SDA+ and Medium B+, in order to synergistically isolate and detect the greatest
number of fungi present in CF sputa.
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Patients with CF may suffer increased morbidity and
mortality from colonisation, allergic reaction (allergic bronch-
opulmonary aspergillosis; ABPA) and invasive infection, from
yeasts and filamentous fungi. The presence of fungi in thed by Elsevier B.V. All rights reserved.
Table 1
Comparison of growth of eight fungal species on unsupplemented SDA,
Medium B and Medium C
Fungi SDA Medium B Medium C
Aspergillus niger +++ +++ +
Penicillium sp. ++ +++ ++
Mucor sp. − + +
Aspergillus fumigatus +++ +++ +++
Aspergillus flavus ++ ++ ++
Candida albicans + +++ +
Candida dubliniensis + +++ +
Candida parapsilosis + +++ ++
+++, confluent growth; ++, semi-confluent growth; +, few; −, no growth.
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transplantation. The frequent recovery of Aspergillus spp. from
respiratory tract secretions is well recognised. However, there
have been very few reports of other fungi being of clinical
significance in CF patients and the isolation rates of fungi from
CF patients vary widely in the reported literature. One possible
reason for the under-reporting of such mycological agents in CF
may be due to inadequacies in the microbiological detection of
fungi in sputum from CF patients, which is relatively insensitive
and requires significant improvement, due to difficulties in
cultural separation of the yeasts and filamentous fungi from the
patients' sputum from a mainly Gram−ve bacterial flora,
approximating to 108–109 colony forming units of bacteria
(cfu)/ml sputum [1].
Laboratory culture of sputum continues to be the diagnostic
cornerstone in the detection of medically important fungi,
colonising/infecting patients with CF. However, microbiologi-
cal culture specific for fungi is not performed as a routine
examination in most clinical laboratories. However, it is
estimated that many fungi may be missed using this conven-
tional culture method, due to (i), the inhibition of fungal growth
by bacteria, particularly Pseudomonas aeruginosa and Bur-
kholderia cepacia and (ii) overgrowth by rapidly growing
bacterial organisms.
Therefore, the aim of this study was to define a mycological
culture medium that could be employed in routine micro-
biological laboratories supporting CF units, specifically for the
examination of CF sputum with a high burden of bacterial
organisms, in order to promote selectivity and sensitivity in the
recovery of yeasts and filamentous fungi from sputum of adult
patients with CF, whilst inhibiting the bacterial co-flora in the
sputum of these patients.
2. Materials and methods
2.1. Basal medium
Two novel fungal basal media, i.e. “Medium B” and
“Medium C”were formulated and compared against a commonly
employed and commercially available fungal medium, i.e.
Sabouraud Dextrose Agar (SDA), for the ability to proliferate
yeasts and filamentous fungi.MediumBwas formulated based on
calculating mean constituent components from 28 commercially
described fungal culture media (http://www.oxoid.com) and
contained glucose (16.7 g/l), agar (20 g/l), yeast extract (30 g/l)
and peptone (6.8 g/l) at pH 6.3. Medium C was formulated by
employing glucose (20 g/l), agar (20 g/l) and pooled adult CF
sputum (100 g/l). The mean pH of freshly expectorated sputum
from adult CF patients was determined to be 7.3 and the pH of
Medium C was corrected to this value. SDA (Oxoid CM0041,
Oxoid Ltd., Basingstoke, UK) was also included in this study and
consisted of mycological peptone (10.0 g/l), glucose (40.0 g/l),
agar (15.0 g/l) with a pH 5.6±0.2. The specificity of SDA,
MediumB andMediumCwas examined semi-quantitativelywith
eight fungi, selected from an archive of highly characterised
fungal taxa previously isolated from CF sputum, including: As-
pergillus fumigatus, Aspergillus flavus, Aspergillus niger, Can-dida albicans, Candida dubliniensis, Candida parapsilosis,
Mucor sp. and Penicillium sp. SDA, Medium B and Medium C
were streaked individually with 20 μl inocula of each of the above
fungi and incubated aerobically at 37 °C for 1 week, prior to
examination of the resulting plates. Growth was scored in a semi-
quantitative basis, using the range no growth, + (few), ++ and +++
(confluent) growth (see Table 1).
2.2. Addition of selective antibiotic agents to suppress bacterial
co-flora
Six antibiotic agents were included in the basal fungal media
(SDA, Medium B and Medium C) to inhibit the growth of
bacterial co-flora in the sputum, in order to avoid interference
and potential inhibition of fungal growth by bacteria and
overgrowth by rapidly growing bacterial organisms. All
antibiotic agents were obtained from Sigma Corp. (St. Louis,
USA) and included vancomycin, gentamicin, cotrimoxazole,
chloramphenicol, ceftazidime and colistin. Antibiotic suscept-
ibility of 13 species wildtype bacteria, which had been isolated
previously from CF sputum, including. P. aeruginosa (n=5),
Pseudomonas fluorescens (n=1), B. cenocepacia (n=21),
Aeromonas salmonicida (n=1), Alcaligenes sp.(n=1), Acine-
tobacter baumannii (n=1), Klebsiella oxytoca (n=1), Morga-
nella morganii (n=1), methicillin-resistant Staphylococcus
aureus (MRSA) (n=1), Stenotrophomonas maltophilia (n=1),
Proteus mirabilis (n=1) and Methylobacterium mesophilicum
(n=1), were examined with reference to their resistances
against the six selected agents combined in a matrix of 10
combinations of the six agents. Eight of these combinations
employed a combination of three antibiotic agents, with the
remaining two combinations, having the inclusion of six and
four agents, respectively, in order to determine the ability of the
fungal basal media+antibiotic combination, to suppress the
growth of the bacterial isolates examined. All 36 isolates were
prepared by culture of pure inoculum onto Columbia Blood
Agar (Oxoid CM0331) supplemented with 5% (v/v) defribi-
nated horse blood and incubated at 37 °C for 24 h. Following
this, serial dilutions of a stock bacterial suspension (approximately
108 cfu/ml in phosphate buffered saline (PBS)) were prepared and
each bacterial isolates was streaked onto Medium+antibiotic
combination, which was incubated at 22 °C for 72 h and the
568 Y. Nagano et al. / Journal of Cystic Fibrosis 7 (2008) 566–572bacterial growth (if any) was recorded after this time, as the
organisms' susceptibility to the medium, as susceptible [S] (no
bacterial growth observed), intermediately resistant [Int.R]
(poor bacterial growth on medium) or resistant [R] (no
difference in bacterial growth characteristics compared to
control).Table 2
Comparison of SDA, SDA+ and Medium B+ to suppress bacterial growth in 50 isol
Organism
(isolate reference)
SDA
BCC/05/1⁎ Int.R
BCC/05/2 Int.R
BCC/05/3 Int.R
BCC/05/4 Int.R
BCC/05/5 Int.R
BCC/05/6 Int.R
BCC/05/7 S
BCC/05/8 Int.R
BCC/05/9 Int.R
BCC/05/10 Int.R
BCC/05/11 Int.R
BCC/05/12 Int.R
BCC/05/13 Int.R
BCC/05/14 Int.R
BCC/05/15 Int.R
BCC/05/16 Int.R
BCC/05/17 Int.R
BCC CF/05/58 Int.R
P.A CF/05/33⁎⁎ Int.R
P.A CF/05/47 S
P.A CF/05/48 S
P.A CF/05/49 S
P.A CF/05/52 Int.R
P.A CF/05/56 Int.R
P.A CF/05/59 Int.R
P.A CF/05/60 Int.R
P.A CF/05/61 R
P.A CF/05/73 Int.R
P.A CF/05/74 S
P.A CF/05/77 Int.R
P.A CF/05/78 S
P.A CF/05/81 Int.R
P.A CF/05/82 Int.R
P.A CF/05/85 Int.R
Stenotrophomonas maltophilia CF/05/31 S
Staphylococcus aureus Int.R
Methylobacterium mesophilicum CF/04/12 S
E. coli S
Haemophilus influenzae S
Staphylococcus aureus 1-3384 S
Pseudomonas fluorescens S
Morganella morgarii R
MRSA R
Alcaligenes xylosoxidones R
Klebsiella oxytoca R
Alcaligenes sp. R
Aeromonas salmonicida Int.R
Proteus mirabilis R
Pseudomonas fluorescens S
Morganella morgarii R
Susceptible [S] (no bacterial growth observed), intermediately resistant [Int.R] (poor
characteristics compared to control). ⁎, BCC = Burkholderia cepacia comple
cotrimethoxazole, 128 mg/l; chloramphenicol, 50 mg/l; ceftazidime, 32 mg/l; colisti2.3. Comparison of SDA, SDA+ and Medium B+ inhibition of
bacterial isolates from CF sputum
A study was then performed to compare the relative inhibitory
effects of SDA, SDA+ and Medium B+ to suppress the growth of
50 bacterial isolates, as detailed in Table 2. Respectivemediawereates obtained from CF sputum
SDA+ Medium B+
S Int.R
S Int.R
S Int.R
Int.R Int.R
S S
S Int.R
S S
S Int.R
Int.R Int.R
S Int.R
Int.R Int.R
S S
S Int.R
S Int.R
S Int.R
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
S S
Int.R S
S S
S S
S S
S S
S S
Int.R S
S S
S S
S S
S S
bacterial growth on medium) or resistant [R] (no difference in bacterial growth
x; ⁎⁎ PA, Pseudomonas aeruginosa; +, basal medium supplemented with
n, 24 mg/l.
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and examined, as described above. Resulting bacterial growth (if
any) was recorded, as the organisms' susceptibility to the
medium, as susceptible [S] (no bacterial growth observed),
intermediately resistant [Int.R] (poor bacterial growth on
medium) or resistant [R] (no difference in bacterial growth
characteristics compared to control).
2.4. Demonstration of SDA+ (with antibiotics) and Medium B+
(with antibiotics) ability to support proliferation of yeasts and
filamentous fungi
After choosing the most effective basal agar combinations
(SDA, Medium B)+concentration of antibiotics (cotrimethox-
azole, 128 mg/l; chloramphenicol, 50 mg/l; ceftazidime, 32 mg/l;
colistin, 24 mg/l) to suppress bacterial species, we wished to
demonstrate that these basal media+antibiotic combination were
not antagonistic with regard to proliferation of yeast and
filamentous fungi. An experiment was designed, which chal-
lenged the ability to culture fungi on (a) SDA+ (with optimum
antibiotic combination), as detailed above and (b) Medium B+
(with optimum antibiotic combination), as detailed above. Fresh
media were prepared as detailed in (a) and (b) and 10 fungi were
obtained from the Northern Ireland Mycology Reference
Laboratory, Department of Medical Microbiology, The Royal
Group of Hospitals, Belfast, as detailed in Table 3. Fresh
suspension of each fungus was streaked individually onto each of
the two media, and incubated aerobically at 22 °C for 2 weeks,
prior to examination of the resulting plates. Growth was scored in
a semi-quantitative basis, using the range no growth, + (few), ++
and +++ (confluent) growth.
2.5. Demonstration of “proof of principle” of SDA+ and
Medium+ in the recovery of yeasts and filamentous fungi from
sputum of a population of adult patients with CF
Yeasts and filamentous fungi were isolated from the sputum
of a population of 28 CF adults (N18 years old) attending theTable 3
Comparison of fungal growth of 10 fungi (5 yeasts+5 filamentous fungi) on
unsupplemented SDA and on SDA+ and Medium B+
Fungi related to CF SDA SDA+ Medium B+
Filamentous fungi
Aspergillus fumigatus +++ ++ ++
Penicillium sp. +++ ++ ++
Aspergillus versicolor +++ ++ ++
Scedosporium apiospermum ++ + +
Trichosporon sp. +++ +++ +++
Yeasts
Candida albicans +++ +++ +++
Candida dubliniensis +++ +++ +++
Candida parapsilosis +++ ++ +++
Candida glabrata +++ ++ +++
Exophiala dermatitidis +++ + +++
+++, confluent growth; ++, semi-confluent growth; +, few; −, no growth +, basal
medium supplemented with cotrimethoxazole, 128 mg/l; chloramphenicol,
50 mg/l; ceftazidime, 32 mg/l; colistin, 24 mg/l.Northern Ireland Regional Adult CF Centre, Belfast City
Hospital, as part of their routine diagnostic workup (see
Table 4). Sputa (1 ml minimum) specimens were collected
from 28 adult patients with a well characterised history of CF in
sterile (100 ml) plastic disposable containers. Sputum was
collected immediately after a standardized session of phy-
siotherapy and was stored at ambient temperature, before it was
mixed with an equal mass (1:1) of Sputasol (Oxoid SR089A,
Oxoid Ltd., Poole, England) and was incubated in a water bath
at 37 °C for 15 min, before further processing for the detection
of fungi. Processed sputa (20 μl) were inoculated individually
onto fresh SDA, SDA+ and Medium B+ plates, which were
subsequently incubated aerobically at 22 °C for 2 weeks, prior
to examination. Resulting colonial morphologies were noted on
all three media and were further examined by Gram staining and
microscopy and differentiated into bacteria, yeasts and
filamentous fungi.
3. Results
SDA, Medium B and Medium C allowed the proliferation of
fungi examined to varying degrees, as detailed in Table 1. Mean
semi-quantitative scores of ability to culture yeasts and
filamentous fungi, allowed the ranking of the media into the
following order:
Medium B N SDA N Medium C
Medium B demonstrated the greatest proliferation of fungi,
whilst Medium C showed the poorest ability to culture both
filamentous fungi and yeasts. However, it was noted that
Medium C had a bad odour, when made up and this medium had
difficulties regarding constant supply of sufficient sputum for its
make-up. Given this complication, combined with Medium C
being the poorest at allowing the proliferation of fungi, it was
decided to discontinue employment of Medium C in future
basal medium formulations.
Ten different combinations of antibiotics were tested with
Medium B, for their ability to suppress bacterial growth of 36
isolates, obtained previously from CF sputum. The antibiotic
combination, denoted with the superscript + which contained
cotrimethoxazole, 128 mg/l; chloramphenicol, 50 mg/l; cefta-
zidime, 32 mg/l; colistin, 24 mg/l, was determined to be the
most effective at inhibiting the growth of bacteria examined,
with 67% of isolates being sensitive to this combination of
antibiotics. Even though this antibiotic combination was the
most effective combination to inhibit bacterial growth, it still
permitted B. cenocepacia organisms to proliferate, albeit
growth was poor, in comparison to growth of these organisms
in the absence of this combination of antibiotics.
Medium B+ was then compared against SDA and SDA+
(Table 2). Bacterial strains (n=50) including 16 strains of
P. aeruginosa and 18 strains of B. cenocepacia were tested on
SDA, SDA+ and Medium B+. On SDA, even though no
antibiotics were added, 13/50 (26%) were sensitive, 29/50
(58%) had intermediate resistant and 8/50 (16%) were resistant.
The most effective result was obtained on SDA+, where 45/50
Table 4
Employment of SDA, SDA+ and Medium B+ to detect and isolate yeasts and filamentous fungi from sputum taken from a population of 28 Adult CF patients
Patient no. Bacteria Yeasts Filamentous fungi
SDA SDA+ Medium B+ SDA SDA+ Medium B+ SDA SDA+ Medium B+
1 + − − + + + − − −
2 − − − + + + − − −
3 − + − − − − + + +
4 − − − + + + − − −
5 + − − − + + − − −
6 + − − − − + − − −
7 + − − + − + − − −
8 + − + − + − − − −
9 − − − − − + + − −
10 + − + + + + − − −
11 + + + − + + − − −
12 + − − + + + − − −
13 + − − + + + − − −
14 + − − − − − − − −
15 − − − + + + − − −
16 + − − + + + − − −
17 + − − + + + − − −
18 − − − + − − − − −
19 − − − − − − − − −
20 − − − + + + − − −
21 − − − + + + − − −
22 + − − + + + + − +
23 + − − − + + + − +
24 − − − + + + − − −
25 − − − + + + − − −
26 − − − + + + − − +
27 + + + + + + − − −
28 − − − + + + + + +
Total 15/28 3/28 4/28 19/28 21/28 23/28 5/28 2/28 5/28
+, basal medium supplemented with cotrimethoxazole, 128 mg/l; chloramphenicol, 50 mg/l; ceftazidime, 32 mg/l; colistin, 24 mg/l.
Fig. 1. Comparative growth of a pure culture of Exophiala dermatitidis on SDA,
SDA+ and Medium B+. +, basal medium supplemented with cotrimethoxazole,
128 mg/l; chloramphenicol, 50 mg/l; ceftazidime, 32 mg/l; colistin, 24 mg/l. To
view this figure in full colour, please go to the on-line version.
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and none of the organisms examined were resistant. 38/50
(76%) were sensitive, and 12/50 (24%) were intermediately
resistant on Medium B+. Intermediately resistant organisms
were all B. cenocepacia and none of the bacterial organisms
examined grew on this medium except B. cenocepacia.
The ability to culture fungi was also examined on SDA,
SDA+ and Medium B+ (see Table 3). SDAwithout the addition
of any antibiotics was the optimum medium for the proliferation
of the 5 yeasts and 5 filamentous fungi examined. Filamentous
fungal proliferation was reduced on both SDA+ and Medium B+
in comparison with unsupplemented SDA medium, with the
exception of the Trichosporon sp. isolate, which was not
affected by inclusion of the antibiotics. There was no difference
in the growth of yeasts between SDA andMediumB+. However,
the growth of yeasts was inhibited on SDA+, especially Exo-
phiala dermatitidis, which grew poorly on this medium (Fig. 1).
Employment of the developed fungal media, i.e., SDA+ and
Medium B+, along with SDA, allowed the controlled
surveillance of yeasts and filamentous fungi from 28 adult CF
patients, attending the Regional Adult CF centre and results are
shown on Table 4 and Fig. 2. 15/28 sputum grew bacteria on
SDA, only 3 grew on SDA+ and 4 grew on Medium B+. The
combination and concentration of antibiotics chosen succeeded
in inhibiting most of the bacteria which were contained in theCF sputum. SDA could detect yeasts from 19 sputum samples
and SDA+ could detect yeasts from 21 sputum samples.
Medium B+ could detect yeasts from 23 samples, which was the
highest number among the three media tested. In at least four
sputum samples, SDA failed to detect yeasts. Some cases were
Table 5
Comparison of specificity and sensitivity of SDA, SDA+ and Medium B+ for the
detection of yeasts and filamentous fungi
Fungal selective
medium
Specificity
(%)
Yeasts
(%)
Filamentous
fungi (%)
Combined
fungi (%)
SDA 46.4 76.0 83.0 84.6
SDA+ 89.2 84.0 33.0 84.6
Medium B+ 85.7 92.0 83.0 92.3
+, basal medium supplemented with cotrimethoxazole, 128 mg/l; chloramphe-
nicol, 50 mg/l; ceftazidime, 32 mg/l; colistin, 24 mg/l.
Fig. 2. Comparison of colonial morphologies of yeasts and filamentous fungi
isolated from the sputum of an adult CF patient with SDA, SDA+ and Medium
B+. +, basal medium supplemented with cotrimethoxazole, 128 mg/l;
chloramphenicol, 50 mg/l; ceftazidime, 32 mg/l; colistin, 24 mg/l. To view
this figure in full colour, please go to the on-line version.
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because of the overgrowth of rapid growing filamentous fungi.
SDA and Medium B+ could detect filamentous fungi in five
sputa. However, SDA+ could detect filamentous fungi in only
two sputa. As our previous experiment demonstrated, some
fungi were inhibited on SDA+. Although there was clear
inhibition of Pseudomonas and other bacterial growth on the
medium containing antibiotics, there was little difference in
filamentous fungi growth between SDA+ and Medium B+.
The specificity and sensitivity of SDA, SDA+ andMediumB+
for the detection of yeasts and filamentous fungi from sputum of
adult patients with CF, are shown in Table 5. Employment of
SDA+ or Medium B+ allowed an increase in specificity in theFig. 3. Demonstration of bacterial overgrowth on SDA and unsupplemented
Medium by Pseudomonas aeruginosa, from a sputum of an adult patient with
CF. Note how supplementation of Medium B+ with the antibiotic combination
(cotrimethoxazole, 128 mg/l; chloramphenicol, 50 mg/l; ceftazidime, 32 mg/l;
colistin, 24 mg/l), inhibits the bacterial co-flora in the sputum and allows the
proliferation of yeast and filamentous colonial morphologies. To view this figure
in full colour, please go to the on-line version.detection of yeasts and moulds, by 42.8% and 39.3%,
respectively, over SDA when used solely. SDA+ had a greater
ability than Medium B+ to suppress bacterial growth from
predominantly Gram−ve co-colonisers. This is a significant
benefit when attempting to detect and isolate fungi from the
sputum of CF patients, as it largely suppressed any bacterial
growth, with the exception of the BCC organisms, thus allowing
for an increased opportunity to detect target fungal organisms in
sputum and represented a significant improvement over the
commercial medium (SDA), which is currently used. Alterna-
tively, Medium B+ had a great ability to grow fungi than SDA+
and when employed, the specificity of combined use was 85.7%,
with a sensitivity for yeasts, filamentous fungi, and combined
overall fungi of 92.0%, 83.0% and 92.3%, respectively.
4. Discussion
Current US CFF Registry data indicates an approximate
doubling of prevalence of fungi being detected in CF sputum
from 1995 through 2005, rising from approximately 6% in 1995
to approximately 13% in 2005 (personal communication, Bruce
Montgomery, US CFF Foundation). This rise is probably due to
our better understanding of the disease and the manner which
we manage it, in particular, with new and improved antibiotic
interventions. The introduction of improved antibiotic agents
and the way in which we effectively use such agents in double
or triple therapy, as well as in antibiotic cycling, has help
address the requirement to control chronic Gram −ve infections
in CF, but has inadvertently created a niche for the colonisation
and proliferation of fungi in the CF lung. Furthermore, we do
not believe that this marked rise in fungal isolations is due to
any significant improvements in the laboratory isolation of
yeasts and filamentous fungi at primary diagnostic clinical
microbiology laboratories, who support both adult and
paediatric CF centres, as fungal isolation methodology has
gone largely unchanged for the past decade.
Ability to detect and isolate fungi in the sputum of CF patients
is important due to the emerging significance of these organisms
in patients with CF, particularly in relation to (i) ABPA, (ii) post
transplant fungaemia and (iii) chronic colonisation/infection.
Recent data has indicated that ABPA affects approximately 1–
15% of CF patients [2], and is associated with an accelerated
decline in lung function [3]. Most of the mycological aetiology
of this condition is due to A. fumigatus and other Aspergillus sp.
[4], although other fungi have been previously reported [5]. In
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at increased risk of opportunistic fungal infection, such as
invasive pulmonary aspergilloma and other invasive mycoses,
due to the immunosuppression of the host. Thus, it is important
to have the ability to reliably detect, isolate and characterise the
mycological agents causing such conditions from CF sputum.
The aim of the present studywas to develop a selectivemedium
for the isolation of yeasts and filamentous fungi from the sputumof
adult patients with CF. In addition to the clinical reasons for the
efficient isolation of fungi from CF sputa, there are an additional
two microbiological reasons to pursue this aim. Firstly, it has been
shown previously [6] that P. aeruginosa produces a secondary
metabolite, namely pyocyanin, which is inhibitory to fungal
growth. Thus, in the context of the CF lung, large numbers of
P. aeruginosa, which have been shown to colonise/infect the CF
airways, with a bacterial burden of 108–109 cfu/ml sputum, may
mask the presence of fungi, due to the production of pyocyanin.
Secondly, due to the high bacterial burden in CF sputum, fungi
may not be detected due to overgrowth by fast-growing co-
habiting bacterial species, such as Proteus spp. and mucoid P.
aeruginosa. Therefore, it is important to have the cultural ability to
selectively grow fungi from CF sputa, without the inhibitory
effects from other flora, as outlined above.
In designing a new selective medium, we had to consider two
main factors, namely (i) the composition of the basal medium to
nutritionally support the species of fungi normally found in CF
sputa, and (ii) the ability of selective agents to suppress bacterial
co-habitants of CF sputa, but avoidance of suppression of
fungal growth. In consideration of the formulation of a suitable
basal medium, we firstly examined the various constituents of
28 commercially available fungal media. Our analysis showed
that these media consisted of four basic components, namely
glucose, yeast extract, peptone and agar. Many of the media
examined were designed for specific mycological purposes, e.g.
Malt Extract Agar (Oxoid CM0059) for the detection of yeasts
and moulds in foodstuffs. Hence, it was difficult to select a
single formulation from all these combinations for use with CF
sputa. Therefore, we averaged the main constituents across this
range of commercially available media to achieve the formula-
tion of Medium B, namely, glucose (16.7 g/l), agar (20 g/l),
yeast extract (30 g/l) and peptone (6.8 g/l). In addition, we
wished to compose a medium derived solely from CF sputum
(Medium C), which was physiologically closest to conditions in
the CF airways. Therefore, we formulated a simple medium
consisting solely of CF sputum (100 g/l) and agar (20 g/l). Our
initial comparison of SDA, Medium B and Medium C was
carried out to select which basal medium to progress to the
incorporation of antibiotic selective agents. SDA was used
throughout as a comparator, because it is commercially
available and is employed by most clinical microbiology
diagnostic laboratories for the isolation of yeasts and filamen-
tous fungi from clinical specimens, including CF sputa. Both
SDA and Medium B were best at allowing the proliferation of
the fungi challenged, whereas Medium C gave the poorest
growth of selected fungi and hence was not examined further for
this reason, as well as for associated problems with small,
consistency and availability from CF patients.Several experiments were then designed in order to identify a
suitable combination of antibiotic agents that could suppress the
co-habiting bacterial flora, but which would not interfere with
fungal proliferation. Several additional experiments were initially
performed (data not shown), in which the range and concentration
of antibiotics were greater and which inhibited fungal growth, as
well as bacterial growth, even including B. cenocepacia. Selecting
suitable agents and their concentrations presented the greatest
challenge of this study. Examination of CF sputum for the isolation
of fungi is relatively unique,whereby themediumhas to overcome
the problems presented by fast growing and highly resistant
bacteria in sputa, including multi/pan-resistant P. aeruginosa,
mucoid P. aeruginosa, B. cenocepacia and S. maltophilia. A
combination of cotrimethoxazole, 128 mg/l; chloramphenicol,
50 mg/l; ceftazidime, 32 mg/l; colistin, 24 mg/l provided to be the
most effective at minimizing interference from co-habiting
bacterial organisms, with the exception of B. cenocepacia, which
continued to grow, albeit at diminished rates.
In a proof-of-principle study, SDA, SDA+ and Medium B+
were compared for the ability to isolate fungi from the sputum
of a population of 28 adult CF patients. In this study, SDA+
proved to be the most selective fungal medium, whereas
Medium B+ was the most sensitive medium, for the detection of
fungi from CF sputum. Overall, when employing one fungal
selective medium for the routine detection of yeasts and
filamentous fungi in the sputum of CF patients, we would
recommend employment of Medium B+. However, we would
recommend the combined employment of SDA+ and Medium
B+, in order to isolate fungi present in CF sputa.
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